Product Sales (Tables)

6 Months Ended

Jun. 30, 2020

Revenues [Abstract]

Schedule of product sales

Net product sales consist of the following:

	Three Months Ended June 30,				Six Months Ended June 30,
Net Product Sales in the United States	2020		2019		2020			2019
EYLEA®	$	1,113.7	$	1,160.3	$	2,285.7		$	2,234.4
Libtayo®	63.3		40.8		125.0			67.6
Praluent®	47.2		*		47.2		*	*
ARCALYST®	2.7		4.2		5.7			7.7
	$	1,226.9	$	1,205.3	$	2,463.6		$	2,309.7
* Effective April 1, 2020, the Company is solely responsible for the development and commercialization of Praluent in the United States and records net product sales of Praluent in the United States. See Note 3 for further details.

Schedules of Concentration of Risk, by Risk Factor

Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019
Besse Medical, a subsidiary of AmerisourceBergen Corporation	53	%	56	%	53	%	57	%
McKesson Corporation	32	%	34	%	34	%	32	%